Company · Aberdeen

Elasmogen

Elasmogen is a life sciences company based in Aberdeen, incorporated in Scotland in 2014 (SC467513).

What they do

“Elasmogen is a biopharmaceutical company developing next-generation soloMER™ biologics. We specialize in high-affinity, site-specific treatments for solid-tumor cancers and inflammatory diseases.”

In its own words, on elasmogen.com

In plain speak

They develop medicines made from proteins, designed to treat solid cancers and inflammatory diseases.

Grants

Awarded a £528k Ukri Flf grant for "Finding Needles in Haystacks: First-in-class soloMER drug candidates as precision medicine for autoimmune inflammation diseases."

1 Dec 2025 · UKRI Gateway to Research

Partner in a Mrc-funded project, "Enabling enhanced preclinical nuclear imaging at the University of Hull"

31 Oct 2022 · UKRI Gateway to Research

Partner in an Epsrc-funded project, "CageTag: Caged Theranostics as a Universal Platform for Nuclear Medicine"

1 Apr 2022 · UKRI Gateway to Research

Partner in an Ukri Flf-funded project, "Targeting cytotoxic immunity for the resolution of neuropathic pain"

12 Jan 2022 · UKRI Gateway to Research

Awarded a £1.58m Ukri Flf grant for "Targeting the pathogenic Th17 cell axis in autoimmunity:developing a portfolio of novel."

1 Dec 2021 · UKRI Gateway to Research

Awarded a £232k Innovate UK grant for "Bridging critical funding gap to deliver late-stage pre-clinical oncology assets"

1 Jun 2020 · UKRI Gateway to Research

Partner in an Innovate UK-funded project, "Queen's university Belfast and Elasmogen Limited"

1 Nov 2019 · UKRI Gateway to Research

Partner in an Innovate UK-funded project, "University of Aberdeen and Elasmogen Limited"

1 Dec 2018 · UKRI Gateway to Research

Partner in a Bbsrc-funded project, "Uncovering the pharmacology of a novel receptor target for age-related macular degeneration"

1 Oct 2018 · UKRI Gateway to Research

Partner in a Bbsrc-funded project, "SSA Uncovering the pharmacology of a novel receptor target"

1 Oct 2018 · UKRI Gateway to Research

Partner in an Innovate UK-funded project, "A Technology Platform for Next Generation VNAR Based Oncology Medicines"

1 Aug 2018 · UKRI Gateway to Research

Partner in a Bbsrc-funded project, "Development of intracellular VNARs as novel tools to dissect intracellular biological processes"

1 Apr 2018 · UKRI Gateway to Research

Awarded a £686k Innovate UK grant for "soloMER™ Biologics: Next-generation therapeutics for the site-specific treatment of ocular diseases"

1 Feb 2017 · UKRI Gateway to Research

Awarded a £69k Innovate UK grant for "soloMER™ coated Nanoparticles or sNaPs™ - The development of optimised “escort” molecules for the targeted delivery of nanomedicine, anti-cancer therapeutics"

1 Apr 2016 · Innovate UK

Latest from Elasmogen

Elasmogen Ltd is pleased to announce the appointment of Dr Suhail Nurbhai as Chief Medical Officer

15 Jan 2026, from elasmogen.com, posted by the company

Elasmogen and Intract Enter License Agreement for Soteria® and Phloral® Technologies

6 Jan 2026, from elasmogen.com, posted by the company

Elasmogen announces a panel of novel, potent, anti-Covid-19 therapeutic candidates identified through collaboration with U.S. research partners

6 Jan 2026, from elasmogen.com, posted by the company

Elasmogen wins two grants worth £374,000

6 Jan 2026, from elasmogen.com, posted by the company

Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics

6 Jan 2026, from elasmogen.com, posted by the company

Timeline

15 Jan 2026from the companyElasmogen Ltd is pleased to announce the appointment of Dr Suhail Nurbhai as Chief Medical Officer
6 Jan 2026from the companyElasmogen and Intract Enter License Agreement for Soteria® and Phloral® Technologies
6 Jan 2026from the companyElasmogen announces a panel of novel, potent, anti-Covid-19 therapeutic candidates identified through collaboration with U.S. research partners
6 Jan 2026from the companyElasmogen wins two grants worth £374,000
6 Jan 2026from the companyIntract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics
30 Aug 2022directorWilliam Roderick Justin Richards appointed Director
29 Apr 2022directorJane Elizabeth, Dr Dancer appointed Director
5 Apr 2017directorSavvas Ioannou, Dr Neophytou appointed Director
24 Sep 2015directorCaroline Jane, Dr Barelle appointed Director
15 Jan 2014incorporatedElasmogen incorporated as SC467513

Register facts, funding, grants and the latest news, each linked or sourced. The data file holds the register facts, funding and grants only.

Use this data

Download everything ayeoh holds on Elasmogen, free: CSV · JSON-LD. Every row carries its source and date.

Record completeness 56 of 100; not yet held: filed accounts, three years of accounts, turnover, news coverage.

Licence: free to read and cite with a link to ayeoh.io; bulk, API or commercial reuse needs an ayeoh licence. Cite as: ayeoh.io, “Elasmogen”, ayeoh.io/c/elasmogen, accessed 1 Nov 2026.